Program
CDK2 Inhibitor ECI830
In Novartis’s pipeline, CDK2 inhibitor
. Its studies are mostly in Small Cell Lung Carcinoma, led by Novartis.
Furthest: phase 2, since Dec 5, 20241 company-led study, 1 open or runningNext primary completion: Sep 25, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 11 open or running | phase 2since Dec 5, 2024 | Dec 5, 2024 | Sep 25, 2028phase 2 · NCT06726148 |
- Named in Novartis’s own pipeline as
ECI830
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 5, 2024First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT06726148 · 280 planned · United States, Australia, Canada and more
Ahead
- Sep 25, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT06726148
TargetBeta
“CDK2 inhibitor”the company's pipeline, read by Claude · source
“An inhibitor of cyclin-dependent kinase 2 (CDK2), ”NCIt, by rule
Other programs on CDK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| CDK2 Inhibitor INCB123667rule | Incyte | phase 3 | 7 |
| tegtociclib | Pfizer | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
| CDK2 Inhibitor AVZO-021rule | avenzo-therapeutics-inc | phase 2 | 2 |
| CDK2 Degrader BG-75098rule | BeOne Medicines | phase 1 | 1 |
| CG-7321rule | chengdu-cynogen-bio-pharmaceutical-tech-co-ltd | phase 1 | 1 |
| nkt5097 cdk2rule | nikang-therapeutics-inc | phase 1 | 1 |
| ZE94-0605rule | eilean-therapeutics | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06726148Small Cell Lung Carcinoma · United States, Australia, Canada and more | 2 | Recruiting | Sep 25, 2028 | 280 |
How it is read
Names in the registry
- “ECI830”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.